AU8989698A - Optically pure camptothecin analogues, optically pure synthesis intermediate and method for preparing same - Google Patents
Optically pure camptothecin analogues, optically pure synthesis intermediate and method for preparing same Download PDFInfo
- Publication number
- AU8989698A AU8989698A AU89896/98A AU8989698A AU8989698A AU 8989698 A AU8989698 A AU 8989698A AU 89896/98 A AU89896/98 A AU 89896/98A AU 8989698 A AU8989698 A AU 8989698A AU 8989698 A AU8989698 A AU 8989698A
- Authority
- AU
- Australia
- Prior art keywords
- compound
- represented below
- formula
- product
- general formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims description 15
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 title description 12
- 230000015572 biosynthetic process Effects 0.000 title description 4
- 238000003786 synthesis reaction Methods 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 77
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 34
- 150000003839 salts Chemical class 0.000 claims description 28
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 15
- 239000012429 reaction media Substances 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 12
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 claims description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- -1 alkyl radical Chemical class 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical class C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 6
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 claims description 5
- 229910052763 palladium Inorganic materials 0.000 claims description 5
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 4
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 claims description 4
- 150000007522 mineralic acids Chemical class 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 150000007524 organic acids Chemical class 0.000 claims description 4
- 235000005985 organic acids Nutrition 0.000 claims description 4
- 235000009518 sodium iodide Nutrition 0.000 claims description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 3
- 150000001450 anions Chemical class 0.000 claims description 3
- 230000000259 anti-tumor effect Effects 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 3
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 235000019253 formic acid Nutrition 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 235000010755 mineral Nutrition 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000002141 anti-parasite Effects 0.000 claims description 2
- 230000000840 anti-viral effect Effects 0.000 claims description 2
- 239000003096 antiparasitic agent Substances 0.000 claims description 2
- 239000000047 product Substances 0.000 description 41
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 36
- 239000000243 solution Substances 0.000 description 28
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 239000007787 solid Substances 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 239000002244 precipitate Substances 0.000 description 11
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000012300 argon atmosphere Substances 0.000 description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 238000013019 agitation Methods 0.000 description 7
- 229940127093 camptothecin Drugs 0.000 description 7
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- BEIVRAYQIXQZKG-UHFFFAOYSA-N 3-hydroxy-3-[2-methoxy-3-(phenylmethoxymethyl)pyridin-4-yl]pentanoic acid Chemical compound OC(=O)CC(O)(CC)C1=CC=NC(OC)=C1COCC1=CC=CC=C1 BEIVRAYQIXQZKG-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- 239000000010 aprotic solvent Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 229960004132 diethyl ether Drugs 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 101710183280 Topoisomerase Proteins 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 3
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000007363 ring formation reaction Methods 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- OJFSSEVPQSAJLY-UHFFFAOYSA-N (2-chloro-6,7-difluoroquinolin-3-yl)methanol Chemical compound FC1=C(F)C=C2N=C(Cl)C(CO)=CC2=C1 OJFSSEVPQSAJLY-UHFFFAOYSA-N 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- IPOVOSHRRIJKBR-UHFFFAOYSA-N 2-ethylpropanedioyl dichloride Chemical compound CCC(C(Cl)=O)C(Cl)=O IPOVOSHRRIJKBR-UHFFFAOYSA-N 0.000 description 2
- UZOFELREXGAFOI-UHFFFAOYSA-N 4-methylpiperidine Chemical compound CC1CCNCC1 UZOFELREXGAFOI-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- RENMDAKOXSCIGH-UHFFFAOYSA-N Chloroacetonitrile Chemical compound ClCC#N RENMDAKOXSCIGH-UHFFFAOYSA-N 0.000 description 2
- 102000003915 DNA Topoisomerases Human genes 0.000 description 2
- 108090000323 DNA Topoisomerases Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- FZERHIULMFGESH-UHFFFAOYSA-N N-phenylacetamide Chemical compound CC(=O)NC1=CC=CC=C1 FZERHIULMFGESH-UHFFFAOYSA-N 0.000 description 2
- 208000030852 Parasitic disease Diseases 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000010908 decantation Methods 0.000 description 2
- GDTRAYDPXKZJGD-UHFFFAOYSA-N dichlorophosphoryl hypochlorite Chemical compound ClOP(Cl)(Cl)=O GDTRAYDPXKZJGD-UHFFFAOYSA-N 0.000 description 2
- YNLAOSYQHBDIKW-UHFFFAOYSA-M diethylaluminium chloride Chemical compound CC[Al](Cl)CC YNLAOSYQHBDIKW-UHFFFAOYSA-M 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N diisobutylaluminium hydride Substances CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- INWICFYGQUCDBN-UHFFFAOYSA-N ethyl 7-chloro-4-(chloromethyl)-6-methyl-2-oxo-1h-quinoline-3-carboxylate Chemical compound CC1=C(Cl)C=C2NC(=O)C(C(=O)OCC)=C(CCl)C2=C1 INWICFYGQUCDBN-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 229920006395 saturated elastomer Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- SVGNVSSAOZJYGO-UHFFFAOYSA-N 1-(2-amino-4-chloro-5-methylphenyl)-2-chloroethanone Chemical compound CC1=CC(C(=O)CCl)=C(N)C=C1Cl SVGNVSSAOZJYGO-UHFFFAOYSA-N 0.000 description 1
- KHMGMVNRBZRJLT-UHFFFAOYSA-N 2-chloro-6,7-difluoroquinoline-3-carbaldehyde Chemical compound O=CC1=C(Cl)N=C2C=C(F)C(F)=CC2=C1 KHMGMVNRBZRJLT-UHFFFAOYSA-N 0.000 description 1
- SDKQWXCBSNMYBN-UHFFFAOYSA-N 2-chloroquinoline-3-carbaldehyde Chemical compound C1=CC=C2C=C(C=O)C(Cl)=NC2=C1 SDKQWXCBSNMYBN-UHFFFAOYSA-N 0.000 description 1
- JRHWHSJDIILJAT-UHFFFAOYSA-N 2-hydroxypentanoic acid Chemical compound CCCC(O)C(O)=O JRHWHSJDIILJAT-UHFFFAOYSA-N 0.000 description 1
- AXNUZKSSQHTNPZ-UHFFFAOYSA-N 3,4-difluoroaniline Chemical compound NC1=CC=C(F)C(F)=C1 AXNUZKSSQHTNPZ-UHFFFAOYSA-N 0.000 description 1
- RQKFYFNZSHWXAW-UHFFFAOYSA-N 3-chloro-p-toluidine Chemical compound CC1=CC=C(N)C=C1Cl RQKFYFNZSHWXAW-UHFFFAOYSA-N 0.000 description 1
- COYZTUXPHRHKGV-UHFFFAOYSA-N 4-methoxy-5-[3-(2-methoxy-4-nitro-5-sulfophenyl)-5-(phenylcarbamoyl)-1h-tetrazol-2-yl]-2-nitrobenzenesulfonic acid Chemical compound COC1=CC([N+]([O-])=O)=C(S(O)(=O)=O)C=C1N1N(C=2C(=CC(=C(C=2)S(O)(=O)=O)[N+]([O-])=O)OC)N=C(C(=O)NC=2C=CC=CC=2)N1 COYZTUXPHRHKGV-UHFFFAOYSA-N 0.000 description 1
- RVBWWMADTISCJE-UHFFFAOYSA-N 5-ethyl-5-hydroxy-4,8-dihydro-1h-oxepino[3,4-c]pyridine-3,9-dione Chemical compound CCC1(O)CC(=O)OCC2=C1C=CNC2=O RVBWWMADTISCJE-UHFFFAOYSA-N 0.000 description 1
- RXGJTUSBYWCRBK-UHFFFAOYSA-M 5-methylphenazinium methyl sulfate Chemical compound COS([O-])(=O)=O.C1=CC=C2[N+](C)=C(C=CC=C3)C3=NC2=C1 RXGJTUSBYWCRBK-UHFFFAOYSA-M 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 241000759905 Camptotheca acuminata Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010057168 Leishmania infections Diseases 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical group CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
- NDQVUXVYKYLEOS-UHFFFAOYSA-N [2,7-dichloro-4-(chloromethyl)-6-methylquinolin-3-yl]methanol Chemical compound OCC1=C(Cl)N=C2C=C(Cl)C(C)=CC2=C1CCl NDQVUXVYKYLEOS-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960001413 acetanilide Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000012345 acetylating agent Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 125000005604 azodicarboxylate group Chemical group 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- SRFDFLPBCXPCOJ-UHFFFAOYSA-N ethyl 2,7-dichloro-4-(chloromethyl)-6-methylquinoline-3-carboxylate Chemical compound C1=C(Cl)C(C)=CC2=C(CCl)C(C(=O)OCC)=C(Cl)N=C21 SRFDFLPBCXPCOJ-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- QDUXDCXILAPLAG-UHFFFAOYSA-N hydron;1-methylpiperidine;chloride Chemical compound Cl.CN1CCCCC1 QDUXDCXILAPLAG-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- UWVXWJCYPPLTLR-UHFFFAOYSA-N indolizino[1,2-b]quinoline Chemical group C1=CC=CN2C=C(C=C3C(C=CC=C3)=N3)C3=C21 UWVXWJCYPPLTLR-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- IOOMXAQUNPWDLL-UHFFFAOYSA-M lissamine rhodamine anion Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-M 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- PSXXZHPJADTUNB-UHFFFAOYSA-N n-(3,4-difluorophenyl)acetamide Chemical compound CC(=O)NC1=CC=C(F)C(F)=C1 PSXXZHPJADTUNB-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 208000013371 ovarian adenocarcinoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 201000006588 ovary adenocarcinoma Diseases 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- KYKNRZGSIGMXFH-ZVGUSBNCSA-M potassium bitartrate Chemical compound [K+].OC(=O)[C@H](O)[C@@H](O)C([O-])=O KYKNRZGSIGMXFH-ZVGUSBNCSA-M 0.000 description 1
- 239000001472 potassium tartrate Substances 0.000 description 1
- 229940111695 potassium tartrate Drugs 0.000 description 1
- 235000011005 potassium tartrates Nutrition 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000001173 tumoral effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Compounds Of Unknown Constitution (AREA)
- Peptides Or Proteins (AREA)
Description
OPTICALLY PURE ANALOGUES OF CAMPTOTHECIN, OPTICALLY PURE SYNTHETIC INTERMEDIATE AND THEIR PREPARATION PROCESS Camptothecin is a natural compound which has been isolated for the first time from the leaves and the bark of the Chinese plant called camptotheca acuminata (see Wall et al. 5 J. Amer. Chem. Soc. 88:3888 (1966)). Camptothecin is a pentacyclic compound constituted by an indolizino[1,2-b]quinoline fragment fused with an a-hydroxylactone with six links. The carbon in position 20 which carries the a-hydroxy group is asymmetrical and confers a rotatory power on the molecule. The natural form of camptothecin has an absolute "S" configuration as regards the carbon 20 and 10 corresponds to the following formula: 7 'N N 0O HO 0 Camptothecin has an anti-proliferative activity in several cancerous cell lines, including the cell lines of human tumors of the colon, lung and breast (Suffness, M et al: The 15 Alkaloids Chemistry and Pharmacology, Bross A., ed., Vol. 25, p. 73 (Acedemic Press, 1985)). It is suggested that the anti-proliferative activity of camptothecin is related to its inhibitory activity on DNA topoisomerase I. It has been indicated that a-hydroxylactone was an absolute requirement both for the in 20 vivo and in vitro activity of camptothecin (Camptothecins: New Anticancer Agents, Putmesil, M et al, ed., p. 27 (CRC Press, 1995); Wall M. et al, Cancer Res. 55:753 (1995); Hertzberg et al, J. Med. Chem. 32:715 (1982) and Crow et al, J. Med. Chem. 35:4160 (1992)). More recently, the Applicant has perfected a new class of analogues of camptothecin, in which a p-hydroxylactone replaces the natural a-hydroxylactone of 25 camptothecin (cf. Patent Application WO 97/00876). A subject of the invention is a new preparation process for an enantiomerically pure synthetic intermediate, as well as new enantiomerically pure analogues of camptothecin.
-2 Firstly, a subject of the invention is therefore new analogues of camptothecin which are different from any known compound, characterized in that it has the respective formulae (I) and (II) represented below Na
CH
3 F 0 H3C O FN | NI OH 0OH O 0 (I) (II) or in that it is the salts of the compound of formula (II) such as for example that of 5 formula (III) represented below
CH
3 Cl- H, NgCH H3C O 1 ~ N C1 HN
OH
-3 A key intermediate in the synthesis of this type of optically pure compounds is a product of general formula M represented below H NO R 0 HO O M in which R represents a linear or branched alkyl radical containing from I to 10 carbon atoms. Preferably, R represents an ethyl radical. 5 The compounds of formulae (I) and (II) can be prepared in the following fashion: - the compound of formula H N O HO 0 (+)-EHHOPD is coupled respectively with one or other of the compounds of formulae N, or N 2 represented below: CH N 3 N OH
H
3 C OH F NNCl NI
N
2 -4 in order to produce the compound of formula 01 or the compound of formula 02 respectively: 0 F F N - o F NNcO C1 OH N Y CH3
H
3 C N 0O N | -o 02 Cl N CO - compound 01 is then cyclized, and the compound of formula (I) is then obtained; 5 the cyclization of compound 02 produces the compound of formula (II), which can, after salification, produce the compound of formula (III). The formation of compound 01 or 02 starting from the compound of general formula M for which R represents an ethyl radical and N, or N 2 is carried out with a treatment known to a person skilled in the art under the name Mitsunobu's reaction (refer to 10 Mitsunobu, 0. et al. Synthesis, p.
1 (1981)). The hydroxyl function of compound N is displaced by a nucleophile such as compound M or a deprotonated derivative of the latter, by a treatment with a phosphine, for example triphenylphosphine, and an azodicarboxylate derivative, for example diethyl or diisopropyl azodicarboxylate, in an aprotic solvent such as, for example, tetrahydrofuran or NN-dimethylformamide. The 15 cyclization of compounds 01 and 02 in order to produce the compounds of formulae (I) and (II) is preferably carried out in the presence of a palladium catalyst (for example palladium diacetate) under basic conditions (provided for example by an alkaline acetate optionally combined with a phase transfer agent, such as, for example, tetrabutylammonium bromide), in an aprotic solvent such as acetonitrile or NN 20 dimethylformamide, at a temperature comprised between 50'C and 120'C (R. Grigg et al., Tetrahedron 46, page 4003 (1990)).
-5 The invention also offers, as a new industrial product, a compound of general formula M as defined previously. This product can be used for the manufacture of medicaments. The compound of formula M is synthesized according to a new process which is part of the invention and includes the following successive stages: 5 - the racemic t-butyl ester represented below N OMe
OCH
2 Ph R
CH
2 COOtBu OH (for its preparation, refer in particular to the Patent Application WO 97/00876) is treated with trifluoroacetic acid for 18 hours at ambient temperate in order to produce the corresponding carboxylic acid ; - then the quinidine salt of the acid obtained previously is heated in isopropyl alcohol at 10 a temperature greater than 300 C, and preferably at about 500 C, before leaving the reaction medium to cool down to ambient temperatue, so that the salt of one of the enantiomers of the above-mentioned acid crystallizes while the salt of the other enantiomer, the anion of which is represented below, remains in solution N OMe OCH2Ph R''
CH
2 COO OH - the solution in isopropyl alcohol of the salt of the enantiomer which has not 15 crystallized is concentrated and treated with hydrochloric acid and agitated, producing the compound of general formula A represented below -6 N OCH 3
OCH
2 Ph R CH 2 COOH OH A - the compound of general formula A is then put in contact with palladium on damp carbon, then ammonium formate or formic acid is added to the mixture in order to produce the debenzylated product of general formula B represented below N OCH N3 OH R' CH 2 COOH OH B - then the compound of general formula B is cyclized by the action of 5 dicyclohexylcarbodiimide in order to obtain the lactonic compound of general formula C represented below N OCH 3 *3 OH 0 C - finally, the -OCH 3 group of the lactonic compound of general formula C is converted into carbonyl, by the action of sodium iodide and trimethylsilyl chloride, in order to obtain a compound of general formula M represented below.
-7 H N 0 0 OH 0 M For the process described above, the reaction leading from the compound of general formula A to the compound of general formula B will preferably take place in methanol, and preferably by heating the reaction medium to about 400 C after the addition of the ammonium formate. The cyclization of the compound of general formula B in order to 5 produce the compound C can be carried out in THF, preferably at a temperature of about 50' C, while the reaction will preferably be carried out at ambient temperatue with acetonitrile as solvent in the reaction leading from the compound of general formula C to the compound of general formula M. In the particular case where R represents an ethyl group, the compound of formula M is 10 synthesized according to the process constituted by the following successive stages: - the racemic t-butyl ester represented below N OMe OCH 2 Ph CH COOtBu 2 OH (for its preparation, refer in particular to the Patent Application WO 97/00876) is treated with trifluoroacetic acid for 18 hours at ambient temperatue in order to produce the corresponding carboxylic acid ; 15 - the quinidine salt of 3
-(
3 -benzyloxymethyl-2-methoxy-4-pyridyl)-3-hydroxy-pentanoic acid is heated in isopropyl alcohol at a temperature higher than 30' C, and preferably at about 500 C, before leaving the reaction medium to cool down to ambient temperature, so that the salt of the (+) enantiomer of 3-(3-benzyloxymethyl-2-methoxy-4-pyridyl)-3- -8 hydroxy-pentanoic acid crystallizes whilst the salt of the (-) isomer, the anion of which is represented below, remains in solution N, OMe
OCH
2 Ph -''
CH
2 COO OH - the solution in isopropyl alcohol of the salt of the (-) enantiomer of 3-(3 benzyloxymethyl-2-methoxy-4-pyridyl)-3-hydroxy-pentanoic acid is concentrated and 5 treated with hydrochloric acid and agitated, producing the compound of formula A' represented below N OMe
OCH
2 Ph HO
CH
2 COOH A' - the compound A' is then put in contact with palladium on damp carbon, then ammonium formate or formic acid is added to the mixture in order to produce the debenzylated product B' represented below N OMe OH HO
CH
2 COOH B' 10 - then the compound of formula B' is cyclized by the action of dicyclohexylcarbodiimide in order to obtain the lactonic compound of formula C' represented below -9 N OCH 3 0 HO O C, - finally, the -OCH 3 group of the lactonic compound of formula C' is converted into carbonyl, by the action of sodium iodide and trimethylsilyl chloride, in order to obtain (+)-5-ethyl-5-hydroxy-1,3,4,5,8,9-hexahydrooxepino[3,4-c]pyridin-3,9-dione (or (+) EHHOPD) represented below. * H N 0 N 0 HO O (+)-EHHOPD 5 The compound of formula N, can be obtained starting with the aniline of formula P represented below F F NH 2
P
1 according to the following process: the aniline of formula P 1 is N-acetylated by treatment with an acetylating agent such as, for example, acetic anhydride. The 10 acetanilide thus obtained is treated at a temperature comprised between 50'C and I 00 0 C, preferably 75'C, with a reagent known to a person skilled in the art under the name Vilsmeyer's reagent (obtained by the action of phosphoryl oxychloride on NN dimethylformamide at a temperature comprised between 0 0 C and 10 0 C) in order to produce the corresponding 2 -chloro-3-quinolinecarbaldehyde (for example, refer to 15 Meth-Cohn et al. J. Chem. Soc., Perkin Trans. I p.1520 (1981); Meth-Cohn et al. J. Chem. Soc., Perkin Trans. I p.2509 (1981); and Nakasimhan et al. J Am. Chem. Soc., -10 112 p.4431 (1990)). The 2-chloro-6,7-difluoro-3-quinolinecarbaldehyde is easily reduced to the corresponding 2-chloro-6,7-difluoro-3-quinolinemethanol of formula NI, under standard conditions known to a person skilled in the art such as treatment in an alcoholic solvent (for example methanol) with sodium borohydride at a temperature 5 comprised between 0 0 C and 40'C. The compound of formula N 2 can be obtained according to the following process: the aniline of formula P 2 represented below
H
3 C 0 Cl a NH 2 P2 is ortho-acylated by reaction with chloroacetonitrile in the presence of boron trichloride and another Lewis acid such as aluminium trichloride, titanium tetrachloride or 10 diethylaluminium chloride in an aprotic solvent or a mixture of aprotic solvents, followed by hydrolysis (cf Sugasawa T. et al. J. Am. Chem. Soc. 100 p.
4 8 4 2 (1978)). The intermediate thus obtained is then treated with ethylmalonyl chloride in an aprotic solvent such as acetonitrile in the presence of a base such as triethylamine, then treated with an alkaline alcoholate, for example, sodium methylate in methanol, in order to 15 produce ethyl 7-chloro-4-chloromethyl-6-methyl-2-oxo-1,2-dihydro-3-quinoline carboxylate. The latter is converted into ethyl 2,7-dichloro-4-chloromethyl-6-methyl-3 quinolinecarboxylate by treatment with phosphoryl oxychloride. Then a nucleophilic substitution is carried out by treatment with 4-methylpiperidine. The ethyl carboxylate function is then reduced with diisobutylaluminium hydride in an aprotic solvent such as 20 dichloromethane in order to produce the compound of formula N 2 . The order in which the last two stages is carried out may optionally be reversed. Analogues of the intermediate compounds of N 1 or N 2 type have been described in the literature and in particular in the Application PCT 95/05427. The compound of formula (II) can be converted into the form of pharmaceutically 25 acceptable salts according to the usual methods. Acceptable salts include, by way of example and in a non-limitative fashion, the addition salts with inorganic acids such as hydrochloride, sulphate, phosphate, diphosphate, hydrobromide and nitrate or with organic acids such as acetate, maleate, fumarate, tartrate, succinate, citrate, lactate, methane sulphonate, p-toluenesulphonate, pamoate, salicylate, oxalate and stearate. For other examples of pharmaceutically acceptable salts one can refer to "Pharmaceutical Salts", J. Pharm. Sci. 66:1 (1977). The compounds of the present invention possess useful pharmacological properties. 5 Thus the compounds of the present invention have an inhibitory effect on topoisomerase I and/or II and an anti-tumoral activity. The state of the art suggests that the compounds according to the invention have an anti-parasitic and/or anti-viral activity. In this way the compounds according to the present invention can be used in different therapeutic applications. 10 An illustration of the pharmacological properties of the compounds of the invention will be found hereafter in the experimental part. The compounds can inhibit topoisomerase, for example of type I and/or II, in a patient, for example a mammal such as man, by administration to this patient of a therapeutically effective quantity of a compound of formula (I) or of formula (II), or of 15 a pharmaceutically acceptable salt of a compound of formula (II), or also of any mixture of the last-named compounds. The compounds according to the invention have an anti-tumoral activity. They can be used for the treatment of tumors, for example tumors expressing a topoisomerase, in a patient by administration to said patient of a therapeutically effective quantity of a 20 compound of formula (I) or of formula (II), or of a pharmaceutically acceptable salt of a compound of formula (II), or also of any mixture of the last-named compounds. Examples of tumors or cancers include cancers of the oesophagus, the stomach, the intestines, the rectum, the oral cavity, the pharynx, the larynx, the lung, the colon, the breast, the cervix uteri, the corpus endometrium, the ovaries, the prostate, the testicles, 25 the bladder, the kidneys, the liver, the pancreas, the bone, the connective tissues, the skin, the eyes, the brain and the central nervous system, as well as cancer of the thyroid, leukemia, Hodgkin's disease, lymphomas other than those related to Hodgkin, multiple myelomas and others. They can also be used for the treatment of parasitic infections by inhibition of the 30 hemoflagellates (for example in trypanosomia or leishmania infections) or by inhibition of the plasmodia (such as for example in malaria), but also the treatment of viral infections and diseases. These properties make the products of formulae (I) and (II) suitable for pharmaceutical use. A subject of the present Application is also, as medicaments, the products of 35 formulae (I) and (II) as defined above as well as the addition salts with -12 pharmaceutically acceptable mineral or organic acids of the product of formula (II), such as for example the salt of formula (III) described previously, or also of any mixture of the last-named compounds. Similarly the invention relates to the pharmaceutical compositions containing at least one of the medicaments as defined 5 above as active ingredient. Therefore the invention relates to pharmaceutical compositions containing a compound according to the invention or an addition salt with a pharmaceutically acceptable acid of it, in combination with a pharmaceutically acceptable support according to the chosen administration method (for example oral, intravenous, intraperitoneal, intramuscular, 10 transdermic or subcutaneous). The pharmaceutical composition (for example therapeutic) can be in the form of a solid, liquid, liposome or lipidic micella. The pharmaceutical composition can be in solid form, such as for example, powders, pills, granules, tablets, liposomes, gelatin capsules or suppositories. The pill, tablet or gelatin capsule can be covered in a substance which is capable of protecting the 15 composition from the action of gastric acid or enzymes in the stomach of the subject for a sufficient period of time to allow this composition to pass in a non-digested form into the small intestine of the latter. The compound can also be administered locally, for example, at the same location as the tumor. The compound can also be administered according to a sustained release process (for example a sustained release composition or 20 an infusion pump). The appropriate solid supports can be, for example, calcium phosphate, magnesium stearate, magnesium carbonate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine and wax. The pharmaceutical compositions containing a compound according to the invention can also be presented in liquid form such as, for 25 example, solutions, emulsions, suspensions or a sustained release formulation. The appropriate liquid supports can be, for example, water, organic solvents such as glycerol or glycols such as polyethylene glycol, similarly their mixtures, in varied proportions, in water. A subject of the invention is also the use of the products of formulae (I) and (II) as 30 defined above, or addition salts with pharmaceutically acceptable mineral or organic acids of a product of formula (II), such as for example the salt of formula (III) described previously, or also a mixture of the last-named compounds, for the preparation of medicaments intended to inhibit topoisomerase and more particularly topoisomerases of type I or type II, medicaments intended for the treatment of tumors, 35 medicaments intended for the treatment of parasitic infections, as well as medicaments intended for the treatment of viral infections or diseases.
- - 13 The dose of a compound according to the present invention envisaged for the treatment of the diseases or disorders mentioned above, varies according to the administration method, the age and body weight of the subject to be treated as well as the state of the latter and it will be decided definitively by the attending doctor or vet. Such a quantity 5 determined by the attending doctor or vet is here called "effective therapeutic quantity". Unless defined in another manner, all the technical and scientific terms used here have the same meaning as that commonly understood by an ordinary specialist in the field to which the invention belongs. Similarly, all publications, Patent Applications, all Patents and all other references mentioned here are incorporated by way of reference. 10 The following examples are presented to illustrate the above procedures and must in no case be considered as a limit to the scope of the invention. EXPERIMENTAL PART: Example 1: (+)-5-Ethyl-5-hydroxy-1,3,4,5,8,9-hexahydrooxepino[3,4-clpyridin 3,9-dione [(+)-EHHOPD] 15 L.a. Quinidine salt of 3
-(
3 -benzyloxymethyl-2-methoxy-4-pyridyl)-3-hydroxy pentanoic acid: Tertiobutyl 3-(3-benzyloxymethyl-2-methoxy-4-pyridyl)-3-hydroxy-pentanoate (40 g; 100 mmol) is treated with trifluoroacetic acid (150 ml) and the reaction medium is agitated for 18 hours at 20'C. After evaporation of the trifluoroacetic acid, methylene 20 chloride (200 ml) is poured in and a saturated solution of sodium bicarbonate is introduced until the pH = 7.5-8. After decantation, the aqueous phase is washed with 100 ml of methylene chloride. The pH of the aqueous phase is then adjusted to 1 by the addition of a solution of 6N hydrochloric acid. The product is then extracted from the aqueous phase with methylene chloride (2 times 200 ml). The solution is dried over 25 magnesium sulphate and concentrated. The 3 -(3-benzyloxymethyl-2-methoxy-4 pyridyl)-3-hydroxy-pentanoic acid (31.1 g; 90 mmol) thus obtained, taken up in isopropyl alcohol (30 ml), is treated with a solution of quinidine (29.2 g; 90 mmol) in isopropyl alcohol (30 ml) at 50'C under agitation until complete dissolution. Then the reaction medium is left so that temperature reduces to 40'C, the agitation is stopped and 30 the temperature allowed to drop to 20'C. The medium is taken to 0 0 C without agitation then maintained at this temperature for 16 hours. Then the temperature is allowed to rise to 20'C and agitation is carried out until crystallization. The medium is diluted with isopropyl alcohol then filtered. The precipitate is rinsed with isopropyl alcohol. The salt of the (+) enantiomer precipitates (m=26.6 g) while the salt of the (-) enantiomer -14 remains in solution in the isopropyl alcohol. Thus the filtrate is recovered which is concentrated in order to produce an oil (34 g) which is used without other purification in the following stage. The products are analyzed by HPLC on a 5pt CHIRAL AGP column (10 cm x 4mm) 5 eluted with a 30/920/50 isopropyl alcohol/water/phosphate buffer mixture, pH = 6.5, at a flow rate of 1.2 ml/min, UV detection at 280 nm. The retention times obtained are 6.4 minutes for the (-) enantiomer and 2.8 minutes for the (+) enantiomer. The (-) enantiomer / (+) enantiomer ratio is 83/17. 1.b. (-)- 3 -(3-benzyloxymethyl-2-methoxy-4-pyridyl)-3-hydroxy-pentanoic acid 10 The solution in isopropyl alcohol of the quinidine salt of the (-) enantiomer of 3-(3 benzyloxymethyl-2-methoxy-4-pyridyl)-3-hydroxy-pentanoic acid (Stage 1.a) is concentrated. The concentrate is taken up in 270 ml of methylene chloride and 270 ml of a IN solution of hydrochloric acid. The reaction medium is agitated for 16 hours at 20'C. After decantation, the organic phase is concentrated, the concentrate is taken up 15 in methanol in order to be used in the following stage. 13.5 g of product (yield of 87%) and a (-)enantiomer / (+) enantiomer proportion of 85/15 are obtained. The HPLC retention times (same protocol as in L.a.) are: - (-) enantiomer: 6.4 minutes 20 - (+) enantiomer: 2.8 minutes 1.c. (+)-5-Ethyl-5-hydroxy-1,3,4,5,8,9-hexahydrooxepino[3,4-cl pyridin-3,9-dione: (-)-3-(3-benzyloxymethyl-2-methoxy-4-pyridyl)-3-hydroxy-pentanoic acid (13.5 g; 39 mmol; Stage 1.b) is put in solution in 87 ml of methanol. This solution is poured under 25 nitrogen onto 10% Palladium on damp carbon at 50% (27.7 g; 13 mmol). The reaction medium is agitated for 5 minutes, then it is poured into a solution of ammonium formate (11,5 g; 183 mmol) in 135 ml of methanol. The reaction medium is agitated for 30 minutes while allowing the temperature to rise, then it is heated at 40'C for 30 minutes. The medium is then filtered on a bed of Clarcel followed by concentrating. 40 30 ml of toluene is poured in which is evaporated off; this operation is repeated in order to eliminate the methanol. The residue thus obtained is taken up in 45 ml of THF. Then a solution of dicyclohexylcarbodiimide (7.180 g; 34.5 mmol) in 20 ml of THF is then poured in. The reaction medium is heated to 50'C for 1 hour. The mixture is taken to 20'C then the dicyclohexylurea is filtered. The filtrate is concentrated to dryness. The -15 residue is put in solution in 46 ml of acetonitrile, 6.0 g (40.5 mmol.) of sodium iodide then 5.13 ml (40.5 mmol) of trimethylsilyl chloride are added. The reaction medium is maintained under agitation at ambient temperatue for 5 hours. Then 28 ml of acetonitrile and 5.6 ml of water are added. The precipitate obtained is filtered then taken 5 up in 1 ml of water, and the pH is adjusted to 7.5 by the addition of a solution of ammonium hydroxide. The solid obtained is filtered and dried. m= 4.2 g of final product is obtained with a yield of 34 % and a (+) enantiomer / (-) enantiomer proportion of 88.4/11.6. 10 HPLC analysis is carried out on a Chiralcel OD column 25 cm x 4.6 mm, the eluants used are heptane 600 and ethanol 400, the flow rate is 1 ml/min 210 nm. The retention times obtained are: - (-) enantiomer: 7.1 minutes - (+) enantiomer: 9 minutes. The product is taken up in acetone (40 ml), then water (150 ml) is added. The reaction 15 is left to precipitate and 3 g of product is obtained with a (+) enantiomer / (-) enantiomer proportion of 99.4 / 0.6. NMR I H (250 MHz, DMSO D6): 0.8 (t, 3H, CH 3
-CH
2 ); 1.65 (m, 2H, CH 2
-CH
3 ); 3.00 3.35 (q, 1H+1H, -CH 2 -C=O); 5.3 (q, 2H, CH 2 -0); 5.7 (s, -OH); 6.35 (d, aromatic 1H); 7.3 (d, aromatic 1 H); 11.7 (s, N-H). 20 Example 2: (+)-5-ethyl-9,10-difluoro-5-hydroxy-4,5,13,15-tetrahydro-1H,3H oxepino[3',4 ':6,7]indolizino[1,2-bJquinoline-3,15-dione 2.a. N-(3,4-difluorophenyl)acetamide: A mixture of 3,4-difluoroaniline (50 ml; 0.5 mole) and triethylamine (70 ml; 0.5 mol) in dichloromethane (1.5 1) is cooled down using an ice bath. Acetic anhydride (71.5 ml; 25 0.75 mol) is added dropwise and the reaction mixture is then agitated for 1 hour at ambient temperatue. The mixture obtained is then washed successively with water, a 10% solution of sodium bicarbonate and saturated salt water. The organic fraction is dried over sodium sulphate and concentrated under reduced pressure. The residue is suspended in pentane, filtered and dried under reduced pressure in order to produce the 30 product in the title (78 g; 91 % yield) in the form of a whitish solid (M.p. 126-127.5'C). NMR IH (DMSO): 2.15 (s, 3H); 7.10-7.65 (in, 2H); 7.65-8.10 (in, 1H); 10.30 (wide peak, 1H). 2.b. 2 -chloro-6,7-difluoro-3-quinoline-3-carbaldehyde: -16 The general procedure described by Meth-Cohn et al., J Chem. Soc. Perkin Trans. I, 1981, 1520 and 2509 is used. The product of Stage 2.a (32 g; 220 mmol) is added to a Vilsmeyer reagent, obtained by the dropwise addition under an argon atmosphere of phosphorus oxychloride (103 ml; 5 1.1 mol) in anhydrous DMF (34 ml; 440 mmol) cooled down in an ice bath and agitated for 30 minutes before leaving the temperature to rise to ambient temperature. The mixture thus obtained is agitated at 70'C for 16 hours. After returning the reaction medium to ambient temperature, it is added dropwise to a water-ice mixture (400 ml) and agitated for 2 hours. The precipitate obtained is filtered and washed with water, 10 then dried in order to produce the product in the title (9 g; 18 % yield) in the form of a yellow solid (M.p. 226.5-229'C). NMR IH (DMSO): 8.17 (dd, 1H); 8.39 (dd, 1H); 8.97 (d, 1H); 10.34 (d, 1H). IR (KBr): 888, 1061, 1262, 1507, 1691 cm-. 2.c. 2 -chloro-6,7-difluoro-3-quinolylmethanol: 15 A suspension of the product of Stage 2.b (9 g; 39 mmol) in methanol (400 ml) is treated with sodium borohydride (2 g; 53 mmol) at ambient temperature for half an hour. The excess borohydride is destroyed with acetic acid (2 ml). The volatile substances are eliminated under reduced pressure. The residue is dissolved in ethyl acetate (500 ml), the mixture obtained then being washed successively with a dilute solution of sodium 20 bicarbonate, water and saturated salt water, followed by drying over magnesium sulphate and concentration under reduced pressure. The residue is recrystallized from 1,2-dichloroethane in order to produce the product in the title (8 g; 80 % yield) in the form of a beige solid (M.p. 166.5-167'C). NMR IH (DMSO): 4.67 (d, 2H); 5.80 (t, 1H); 8.01 (dd, 1H); 8.22 (dd, 1H); 25 8.48 (s, 1H). IR (KBr): 871, 1038, 1253, 1513 cm- 1 . 2.d. (+)- 8
-(
2 -chloro-6,7-difluoro-3-quinolinemethanol)-5-ethyl-5-hydroxy 1,3,4,5,8,9-hexahydrooxepino[3,4-clpyridine-3,9-dione: Diethylazodicarboxylate (1.24 ml; 7.87 mmol) is added dropwise at ambient 30 temperature and under an argon atmosphere to a solution in anhydrous DMF (30 ml) of (+)-EHHOPD (1.58 g; 7.08 mmol; Stage 1.c.), the product of Stage 2.c (1.62 g; 7.06 mmol) and tributylphosphine (1.91 ml; 7.87 mmol). The mixture thus obtained is then agitated for 16 hours. The reaction medium is then evaporated to dryness under reduced pressure. The residue is purified by chromatography on a silica column (eluant: 35 ethyl acetate). The solid obtained is taken up in diethylether, filtered and dried in order -17 to produce the product in the title (1.56 g; 51 % yield) in the form of a whitish solid (M.p. 196'C). NMR IH (DMSO): 0.84 (t, 3H); 1.74 (m, 2H); 3.02 (d, 1H); 3.34 (d, 1H); 5.29 (s, 2H); 5.31 (dd, 2H); 5.75 (s, 1H); 6.51 (d, 1H); 7.80 (d, 1H); 8.03 (dd, 1H); 8.07 (s, 1H); 8.17 5 (dd, 1H). IR (KBr): 875, 1057, 1360, 1507, 1574, 1647, 1749 cm- 1 . 2.e. (+)- 5 -ethyl-9,10-difluoro-5-hydroxy-4,5,13,15-tetrahydro-1H,3H oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione: A mixture of the product of Stage 2.d (1.53 g; 3.52 mmol; Stage 2.d.), 10 tetrabutylammonium bromide (1.25 g; 3.87 mmol), potassium acetate (520 mg; 5.28 mmol), triphenylphosphine (180 mg; 0.70 mmol) and palladium (II) acetate (79 mg; 0,35 mmol) is agitated under an argon atmosphere in anhydrous acetonitrile heated at reflux for 22 hours. After the reaction medium has returned to ambient temperature, concentration under reduced pressure is carried out before chromatography 15 on a silica column (eluant: CH 2 Cl 2 /MeOH mixture 98/2). The product in the title is then obtained (960 mg; yield 68 %; purity determined by HPLC: 97.1 %). This product is taken up in anhydrous CH 2 Cl 2 (100 ml) and agitation is carried out for 24 hours, followed by filtering and drying under reduced pressure in order to produce the purified product of the title (850 mg; yield 61 %; purity determined by HPLC: 99.6 %) in the 20 form of a white solid. NMR IH (DMSO): 0.87 (t, 3H); 1.85 (m, 2H); 3.08 (d, 1H); 3.44 (d, 1H); 5.26 (s, 2H); 5.39 (d, 2H); 5.52 (d, 2H); 5.99 (wide peak, 1H); 7.39 (s, 1H); 8.15 (dd, 1H); 8.23 (dd, 1H); 8.68 (s, 1H). IR (KBr): 871, 1261, 1512, 1579, 1654, 1746 cm- 1 . 25 Example 3: (+)1-[9-chloro-5-ethyl-5-hydroxy-I 0-methyl-3,15-dioxo-4,5,13,15 tetrahydro-1H,3H-oxepino[3 ',4 ':6,7]indolizino[1,2-bjquinolin-12 ylmethyll-4-methyl-hexahydropyridinium chloride 3.a. 1-( 2 -amino- 4 -chloro-5-methylphenyl)-2-chloro-ethanone: 3-chloro-4-methylaniline (44.4 ml; 0.366 mol) in 1,2-dichloroethane (440 ml), under an 30 argon atmosphere, is cooled down in an ice bath. The following are added dropwise and in the order of this mixture: boron trichloride (IM in heptane; 400 ml; 0.4 mol), chloroacetonitrile (28 ml; 0.44 mol) and diethylaluminium chloride (IM in heptane; 400 ml; 0.4 mol). For the addition, the temperature is maintained below 20' C. The resultant mixture is then heated at reflux for 3 hours, then cooled down to 10' C. The hydrolysis 35 of the reaction medium is then carried out cautiously using 2N hydrochloric acid (240 -18 ml) and it is heated at reflux for 1 hour. Water (11) and ethyl acetate (11) are added, the mixture obtained is agitated for 15 minutes before separating the phases. The aqueous phase is again extracted with ethyl acetate (200 ml), and the combined organic phases are washed with water (500 ml). After drying over magnesium sulphate the organic 5 phase is concentrated. The residue is taken up in petroleum ether (fraction having a boiling point of 45 to 60'C; 150 ml) and the mixture thus obtained is left for 16 hours at 4'C. The resultant precipitate is collected by filtration, washed with petroleum ether and dried under reduced pressure in order to produce the product in the title (25 g; 31 % yield). M.p. 129-130'C. 10 NMR 1H (DMSO): 2.20 (s, 3H); 4.98 (s, 2H); 6.90 (s, 1H); 7.15 (wide peak, 2H); 7.70 (s, 1H). IR (KBr): 871, 1018, 1183, 1225, 1270, 1533, 1577, 1619, 1662 cm-1. 3.b. Ethyl 7 -chloro-4-chloromethyl-6-methyl-2-oxo-1,2-dihydro-3 quinolinecarboxylate: 15 The product of Stage 3.a (25 g; 0.11 mol) and triethylamine (30.6 ml; 0.22 mol) are mixed together in acetonitrile (520 ml). Ethylmalonyl chloride (28.1 ml; 0.22 mol) is added at ambient temperature and under an argon atmosphere. The mixture obtained is agitated for 3 hours. Sodium ethanolate (prepared by the dissolution of 3 g, i.e. 0.13 mol, of sodium in 140 ml of absolute ethanol) is then added dropwise and the resultant 20 mixture is agitated at ambient temperature for 16 hours. The precipitate is collected by filtration, washed successively with ethanol, water, ethanol and ether. It is then dried under reduced pressure at 70'C over phosphorus pentoxide in order to produce the product in the title (28.6 g; 83 % yield) in the form of a whitish powder. NMR 1H (DMSO): 1.30 (t, 3H); 2.40 (s, 3H); 4.35 (q, 2H); 4.85 (s, 2H); 7.41 (s, 111); 25 7.91 (s, 1H); 12.15 (wide peak, 1H). IR (KBr): 879, 1108, 1250, 1288, 1483, 1664, 1721 cm-. 3.c. Ethyl 2
,
7 -dichloro- 4 -chloromethyl-6-methyl-3-quinolinecarboxylate: The product of Stage 3.b (28.4 g; 90 mmol) is heated for 4 hours at reflux in phosphorus oxychloride (400 ml). The mixture obtained is concentrated under reduced pressure (20 30 mm Hg) at 80'C. The residue is taken up in diisopropylether (400 ml). The resultant precipitate is collected by filtration, washed with ether and petroleum ether, then dried under reduced pressure in order to produce the product in the title (25.4 g; 85 % yield) in the form of a whitish powder (M.p. 126-127 0 C). NMR 1H (DMSO): 1.37 (t, 3H); 2.58 (s, 3H); 4.49 (q, 2H); 5.14 (s, 2H); 8.16 (s, 111); 35 8.35 (s, 1H). IR (KBr): 874, 1006, 1163, 1243, 1278, 1577, 1723 cm- 1
.
-19 3.d. 2,7-dichloro-4-chloromethyl-6-methyl-3-quinolylmethanol: The product of Stage 3.c (25.2 g; 76.5 mmol) is mixed under an argon atmosphere with dichloroethane (630 ml). Diisobutylaluminium hydride (IM in dichloromethane; 307 ml; 307 mmol) is added dropwise while the reaction mixture is agitated and the 5 temperature is maintained below 20'C. The reaction mixture is then agitated at ambient temperature for 3 hours, then poured into an aqueous solution of potassium tartrate (concentrated to 20 % by weight; 1.5 1). The emulsion thus obtained is agitated vigorously for 1 hour, filtered on celite and the two phases are then separated. The aqueous phase is extracted with ethyl acetate (200 ml) and the combined organic phases 10 are washed with an aqueous solution of sodium chloride (concentrated to 20 % by weight; 500 ml). The organic phase obtained is dried over magnesium sulphate, filtered and concentrated under reduced pressure. The residue is taken up in diethylether (50 ml) and the resultant precipitate is collected by filtration. By drying under reduced pressure, the product in the title is obtained (18.3 g; 93 % yield) in the form of a whitish powder 15 (M.p. 169-170'C). NMR 'H (DMSO): 2.57 (t, 3H); 4.84 (s, 2H); 5.36 (s, 2H); 8.06 (s, 1H); 8.27 (s, 1H). IR (KBr): 870, 1022, 1102, 1304, 1482, 1567 cm- 1 . 3.e. 2
,
7 -dichloro-6-methyl-4-(4-methylpiperidinomethyl)-3-quinolylmethanol: A solution of the product of Stage 3.d (16.2 g; 55.7 mmol) in THF (70 ml) is treated 20 with a solution of 4-methylpiperidine (23 ml; 195 mmol). The mixture obtained is agitated at ambient temperature for 2 hours. Water (200 ml) and dichloroethane (200 ml) are added. The organic phase is washed with an aqueous solution of sodium chloride (concentrated to 20 % by weight; 100 ml), dried over magnesium sulphate and concentrated under reduced pressure. By crystallization of the residue from diethylether, 25 the product in the title is obtained (18.3 g; 93 % yield) in the form of a white crystalline solid (M.p. 170-171.5'C). NMR 'H (CDCl 3 ): 0.88 (d, 3H); 1.17 (m, 2H); 1.42 (m, 1H); 1.60 (m, 2H); 2.19 (t, 2H); 2.56 (s, 3H); 2.82 (d, 2H); 4.02 (s, 2H); 4.93 (s, 2H); 6.36 (wide peak, 1H); 7.95 (s, 1H); 8.02 (s, 1H). 30 IR (KBr): 971, 1013, 1105, 1293, 1479, 1559 cm- 1 . 3.f. (+)-8-[2,7-dichloro-6-methyl-4-(4-methylpiperidinomethyl)-3 quinolylmethyll-5-ethyl-5-hydroxy-1,3,4,5,8,9-hexahydrooxepino[3,4-c]pydidine 3,9-dione: A suspension of (+)-EHHOPD (obtained in Stage 1.c.; 1.56 g; 7,0 mmol) in anhydrous 35 dioxane (70 ml) is treated successively, under an argon atmosphere, with the product of -20 Stage 3.e (2.47 g; 7.0 mmol), triphenylphosphine (2.02 g; 7.7 mmol) and diisopropyl azodicarboxylate (1.07 ml; 10.5 mmol). The mixture is agitated at ambient temperature for 16 hours. The volatile substances are then evaporated off under reduced pressure. The residue is purified by chromatography on a silica column (eluant: ethyl acetate). 5 The solid obtained is taken up in diethylether, filtered and dried in order to produce the product in the title (1.96 g; 50 % yield) in the form of a whitish solid (M.p. 182'C). NMR 'H (DMSO): 0.89 (in, 8H); 1.23 (in, 1H); 1.41 (t, 2H); 1.64 (in, 2H); 2.09 (q, 2H); 2.59 (in, 5H); 3.15 (dd, 2H); 4.06 (dd, 2H); 5.31 (dd, 2H); 5.35 (dd, 2H); 5.75 (s, 1H); 6.29 (d, 1H); 7.17 (d, 1H); 8.06 (s, 1H); 8.46 (s, 1H). 10 IR (KBr): 878, 1053, 1275, 1474, 1572, 1648, 1747 cm- 1 . 3.g. (+)-9-chloro-5-ethyl-5-hydroxy-10-methyl-12-(4-methylpiperidinomethyl) 4,5,13,15-tetrahydro-1H,3H-oxepino[3',4':6,7]indolizino[1,2-c]quinoline-3,15 dione: A mixture of the product of Stage 3.f (3.80 g; 6.80 mmol), tetrabutylammonium 15 bromide (2.42 g; 7.5 mmol), potassium acetate (1.00 g; 10.2 mmol), triphenylphosphine (890 mg; 3.4 mmol) and palladium (II) acetate (220 mg; 0,68 mmol) is agitated under an argon atmosphere in anhydrous acetonitrile (85 mg) at reflux for 24 hours. After cooling down to ambient temperature, the resultant precipitate is collected by filtration and washed successively with acetonitrile, water, acetone and diethylether in order to 20 produce, after drying under reduced pressure, the product in the title (2.5 g; 70 % yield) in the form of a whitish powder. NMR 1H (DMSO): 0.86 (in, 6H); 1.12 (q, 2H); 1.36 (in, 1H); 1.56 (d, 2H); 1.84 (q, 2H); 2.12 (t, 2H); 2.56 (s, 3H); 2.83 (dd, 2H); 3.26 (dd, 2H); 4.03 (dd, 2H); 5.28 (dd, 2H); 5.45 (dd, 2H); 6.04 (s, 1H); 7.34 (s, 1H); 8.14 (s, 1H); 8.38 (s, 1H). 25 IR (KBr): 870, 1058, 1208, 1280, 1477, 1593, 1655, 1749 cm- 1 . 3.h. (+) 1-[(5R)-9-chloro-5-ethyl-5-hydroxy-10-methyl-3,15-dioxo-4,5,13,15 tetrahydro-1H,3H-oxepino[3',4':6,7]indolizino[1,2-c]quinolin-12-ylmethyl]-4 methyl-hexahydropyridinium chloride: A mixture of the product of Stage 3.g (2.3 g; 7.7 mmol) and absolute ethanol (300 ml) 30 is subjected to ultrasound for 2 minutes. The milky suspension obtained is agitated and treated with hydrochloric acid (IN solution; 13.2 ml; 13.2 mmol) in order to produce a light yellow solution which, at rest, forms a gel-type precipitate. The precipitate is collected by filtration on a Btichner and washed successively with ethanol and ether, then dried under reduced pressure in order to produce the product in the title (2.1 g; 35 85 % yield).
-21 NMR IH (DMSO): 0.87 (m, 6H); 1.59 (m, 5H); 1.84 (q, 2H); 2.64 (s, 3H); 3.28 (dd, 2H); 3.45 (s, 2H); 4.93 (s, 2H); 5.47 (dd, 2H); 5.61 (s, 2H); 6.04 (wide peak, 1H); 7.41 (s, 1H); 8.28 (s, 1H); 8.63 (s, 1H); 10.30 (wide peak, 1H). IR (KBr): 1043, 1212, 1479, 1585, 1655, 1751 cm- 1 . 5 -22 PHARMACOLOGICAL STUDY OF THE PRODUCTS OF THE INVENTION Test on cell proliferation. Five tumoral cell lines are used in this study: SW620 (human colon adenocarcinoma), OVCAR-5 (human ovary adenocarcinoma), PC-3 and DU 145 (cell line of human 5 prostate) and NCI-H69 (human lung adenocarcinoma). These lines are obtained from the NCI/Frederick Cancer Research and Development Center (Frederick, MD). They are cultured in complete medium containing RMPI-1640 medium enriched with 10 % of foetal calf serum and 2 mM of L-Glutamine. They are incubated at 37 0 C in a humidified atmosphere with 5 % of CO 2 . The adherent cells are detached by a treatment with a 10 solution with 0,25 % trypsine and 0.2% EDTA (Worthington Biochemical Corp., Freehold, NJ) for 5 minutes at 37 0 C. Counting the cells is carried out using a Coulter ZI counter (Coulter Corp., Hialeah, FL). The viability is evaluated by staining the cells with propidium iodide then they are counted with an EPICS Elite flow cytometer (Coulter). 15 The compound of Examples 2 and 3 to be tested is dissolved at 5 mM in a solution of N,N-dimethylacetamine (DMA, Aldrich). Subsequent dilutions are carried out with -6 -7 -8 -9 culture medium. The tested final molar concentrations are: 1.10 , 2.10 , 4.10 , 8.10 -9 -10 -11 -11 -12 -13 1,6.10 , 3,2.10 , 6,4.10 , 1,28.10 , 2,56.10 , and 5,12.10 . Each concentration is tested on eight wells. Checks on the influence of DMA are carried out on all the cell 20 lines. The result of these checks is that at the maximum concentration used (0.02 %) the -7 -7 DMA has no effect. Doxorubicin at concentrations of 1.10 M and 2.10 M is used as a positive control. The cells are seeded at 5.10 cells per well on a microplate with 96 wells (Costar Corporation, Cambridge, MA). The cells are incubated for 24 hours at 37 0 C in order to 25 allow a repeat of the cell multiplication. The compound of Examples 2 and 3 to be tested is then added at the concentrations indicated above and the cells are incubated at 37 0 C in a humidified atmosphere with 5 % CO2, for 3 days for the adherent cells (SW620, OVCAR-5, PC-3 and DU 145) and for 5 days for the cells in suspension (NCI H69). 30 The adherent cells are tested by the SRB method (described by L.V. Rubenstein, R.H. Shoemaker, K.D. Paull, R.M. Simon, S. Tosini, P. Skehan, D.A Scudiero, A. Monks, and M.R. Boyd "Comparison of in vitro anticancer-drug-screening data generated with tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines", J. Nat. Cancer Inst., 82:1113-1118, 1990). After incubation for 3 days the 35 supernatant is eliminated and 200 ptl RPMI-1640 free from foetal calf serum is added.
-23 The cells are fixed by the addition of 50 ptl of 50% trichloroacetic (final concentration of trichloroacetic acid 10 %) and incubated at 4'C for 1 hour. The wells are washed 5 times with water then stained with 50 pl of a solution with 0.4 % sulphorhodamine B (SRB, Sigma) in acetic acid at 1 % at ambient temperature for 10 minutes. The stain is 5 solubilized with 100 pl of TRIS buffer at 10 mM, pH 10, for about 5 minutes with agitation, the microplates are read using spectrophotometry at 570 nm. The cells in suspension are tested by the XTT method (described by D.A. Scudiero, R.H. Shoemaker, K.D. Paull, A. Monks, S. Tierney, T.H. Nofziger, M.J. Currens, D. Seniff and M.R. Boyd: "Evaluation of a soluble tetrazolium/formazan assay for cell 10 growth and drug sensitivity in culture using human and other tumor cell lines", Cancer Research 48:4827-4833, 1988). After incubation in the presence of the compound of Examples 2 and 3 to be tested, XTT [sodium salt of 2,3-bis(2-methoxy-4-nitro-5 sulphophenyl)-2H-tetrazolium-5-carboxanilide, (Sigma)] and phenazine methosulphate (PMS, Sigma) in solution in saline phosphate buffer are added to the cultures, and the 15 cells are incubated for 4 hours at 37 0 C in an atmosphere with 5 % CO 2 . The final concentrations of XTT and PMS are 50 and 0.38 pig/well respectively. The production de formazan is stopped by the addition of 10 l of sodium dodecylsulphate at 10 % (Sigma) and the absorbance is read using spectrophotometry at 450 nm with a reference filter at 600-650 nm. 20 Results: The molar concentrations of the compounds of Examples 2 and 3 inhibiting the cell proliferation by 50% are compiled in the following table: Cell line Example 2 Example 3 SW620 5.10-9 3.10-8 OVCAR-5 8.10-9 4.10-8 PC-3 1.10-8 3.10-8 DU 145 1.10-9 7.10-9 NCI-H69 3.10-10 1.10-9
Claims (10)
1. Product characterized in that its formula is one of formulae (I) or (II) represented below No CH 3 F O 3C O NN N N OC NH OH 0OH 0 or in that it is the salts of the compound of formula (II) such as for example that of 5 formula (III) represented below Cl- H, N CHa H3C O N OH (III) -25
2. As a new industrial product, a product of general formula M represented below H N 0 Ril., O OH 0 M in which R represents a linear or branched alkyl radical containing from 1 to 10 carbon atoms.
3. Product according to claim 2, characterized in that R represents an ethyl radical. 5
4 . Preparation process for a product of general formula M represented below, H N O HO 0 M in which R represents a linear or branched alkyl radical containing from 1 to 10 carbon atoms, characterized in that it is constituted by the following successive stages: - the racemic t-butyl ester represented below N OMe OCH Ph 2 R CH COOtBu R OH 2 -26 is treated with trifluoroacetic acid for 18 hours at ambient temperature in order to produce the corresponding carboxylic acid; - then the quinidine salt of the acid obtained previously is heated in isopropyl alcohol at a temperature greater than 30'C, and preferably at about 50'C, before leaving the 5 reaction medium to cool down to ambient temperature, so that the salt of one of the enantiomers of the above-mentioned acid crystallizes while the salt of the other enantiomer, the anion of which is represented below, remains in solution N OMe OCH 2 Ph CH 2 COO OH - the solution in isopropyl alcohol of the salt of the enantiomer which has not crystallized is concentrated and treated with hydrochloric acid and agitated, producing 10 the compound of general formula A represented below N OCH 3 OCH 2 Ph R CH 2 COOH OH A - the compound of general formula A is then put in contact with palladium on damp carbon, then ammonium formate or formic acid is added to the mixture in order to produce the debenzylated product of general formula B represented below N OCH 3 OH CH 2 COOH OH B -27 - then the compound of general formula B is cyclized by the action of dicyclohexylcarbodiimide in order to obtain the lactonic compound of general formula C represented below N OCH 3 OHO 0 C -finally, the -OCH 3 group of the lactonic compound of general formula C is converted 5 into carbonyl, by the action of sodium iodide and trimethylsilyl chloride, in order to obtain a compound of general formula M represented below. H NO <0 OHO 0 M
5. Process according to claim 4, characterized in that R represents the ethyl group.
6. As a medicament, a product characterized in that its formula is one of the 10 formulae (I) or (II) represented below -28 CH 3 N F /0 H3C0 N N 0 F NC1 N OH OH (I) (II) or in that it is an addition salt with pharmaceutically acceptable mineral or organic acids of the product of formula (II) such as for example that of formula (III) represented below CH 3 Cl- H NCH H3C OH 0 5 (III) or also any mixture of the last-named.
7. Pharmaceutical composition containing, as active ingredient, at least one of the compounds of claim 6.
8. Use of a compound according to claim 1 for the preparation of antitumoral 10 medicaments.
9. Use of a compound according to claim 1 for the preparation of antiviral medicaments.
10. Use of a compound according to claim 1 for the preparation of antiparasitic medicaments.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9710785A FR2768431B1 (en) | 1997-08-29 | 1997-08-29 | NOVEL OPTICALLY PURE CAMPTOTHECIN ANALOGS, A NEW OPTICALLY PURE SYNTHESIS INTERMEDIATE AND PROCESS FOR PREPARING THE SAME |
FR9710785 | 1997-08-29 | ||
PCT/FR1998/001768 WO1999011646A1 (en) | 1997-08-29 | 1998-08-07 | Optically pure camptothecin analogues, optically pure synthesis intermediate and method for preparing same |
Publications (2)
Publication Number | Publication Date |
---|---|
AU8989698A true AU8989698A (en) | 1999-03-22 |
AU760863B2 AU760863B2 (en) | 2003-05-22 |
Family
ID=9510590
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU89896/98A Ceased AU760863B2 (en) | 1997-08-29 | 1998-08-07 | Optically pure camptothecin analogues, optically pure synthesis intermediate and method for preparing same |
Country Status (26)
Country | Link |
---|---|
EP (2) | EP1007527B1 (en) |
JP (1) | JP2001514261A (en) |
KR (1) | KR100570254B1 (en) |
CN (3) | CN1195758C (en) |
AR (1) | AR016856A1 (en) |
AT (1) | ATE253069T1 (en) |
AU (1) | AU760863B2 (en) |
BR (1) | BR9811405A (en) |
CA (1) | CA2301739C (en) |
CZ (1) | CZ297896B6 (en) |
DE (1) | DE69819340T2 (en) |
DK (1) | DK1007527T3 (en) |
ES (1) | ES2209196T3 (en) |
FR (1) | FR2768431B1 (en) |
HK (2) | HK1031732A1 (en) |
HR (1) | HRP20000110A2 (en) |
HU (1) | HUP0003429A3 (en) |
IL (2) | IL134437A0 (en) |
NO (1) | NO324882B1 (en) |
NZ (1) | NZ502862A (en) |
PL (1) | PL195289B1 (en) |
PT (1) | PT1007527E (en) |
RU (1) | RU2233283C2 (en) |
TW (1) | TW419479B (en) |
WO (1) | WO1999011646A1 (en) |
ZA (1) | ZA987445B (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2790261B1 (en) | 1999-02-26 | 2004-09-10 | Sod Conseils Rech Applic | NOVEL OPTICALLY PURE CAMPTOTHECIN ANALOGS AND PROCESSES FOR THEIR PREPARATION |
US6207832B1 (en) | 1999-04-09 | 2001-03-27 | University Of Pittsburgh | Camptothecin analogs and methods of preparation thereof |
US6372906B1 (en) | 2001-04-12 | 2002-04-16 | University Of Pittsburgh | Synthesis of silyl camptothecins and silyl homocamptothecins |
US6723853B2 (en) | 2001-08-27 | 2004-04-20 | University Of Pittsburgh | Intermediates and methods of preparation of intermediates in the enantiomeric synthesis of (20R)homocamptothecins and the enantiomeric synthesis of (20R)homocamptothecins |
CN100408582C (en) * | 2004-02-12 | 2008-08-06 | 中国人民解放军第二军医大学 | Homocamptoth-ecine compounds, their preparation process and use |
CA2580747A1 (en) * | 2004-09-21 | 2006-03-30 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R .A.S.) | Novel processes for the production of useful intermediates |
CN100465175C (en) * | 2005-11-29 | 2009-03-04 | 中国人民解放军第二军医大学 | 7-bit substituted comptothecine kind compound and pharmaceutical use thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5459269A (en) * | 1992-06-18 | 1995-10-17 | North Carolina State University | 14-halo-camptothecins |
PT835258E (en) * | 1995-06-21 | 2003-02-28 | Sod Conseils Rech Applic | NEW CAMPOTECETIC ANALOGS, PROCESSES FOR THEIR PREPARATION, ITS USE AS PHARMACEUTICAL COMPOSITIONS AND DRUGS THAT CONTAIN THEM |
-
1997
- 1997-08-29 FR FR9710785A patent/FR2768431B1/en not_active Expired - Fee Related
-
1998
- 1998-08-07 EP EP98941567A patent/EP1007527B1/en not_active Expired - Lifetime
- 1998-08-07 CN CNB031021662A patent/CN1195758C/en not_active Expired - Fee Related
- 1998-08-07 AT AT98941567T patent/ATE253069T1/en active
- 1998-08-07 DK DK98941567T patent/DK1007527T3/en active
- 1998-08-07 CZ CZ20000711A patent/CZ297896B6/en not_active IP Right Cessation
- 1998-08-07 KR KR1020007002034A patent/KR100570254B1/en not_active IP Right Cessation
- 1998-08-07 ES ES98941567T patent/ES2209196T3/en not_active Expired - Lifetime
- 1998-08-07 NZ NZ502862A patent/NZ502862A/en unknown
- 1998-08-07 WO PCT/FR1998/001768 patent/WO1999011646A1/en active IP Right Grant
- 1998-08-07 BR BR9811405-0A patent/BR9811405A/en not_active Application Discontinuation
- 1998-08-07 CN CN98808720A patent/CN1104434C/en not_active Expired - Lifetime
- 1998-08-07 CA CA002301739A patent/CA2301739C/en not_active Expired - Fee Related
- 1998-08-07 RU RU2000107822/04A patent/RU2233283C2/en not_active IP Right Cessation
- 1998-08-07 PT PT98941567T patent/PT1007527E/en unknown
- 1998-08-07 HU HU0003429A patent/HUP0003429A3/en unknown
- 1998-08-07 PL PL98338835A patent/PL195289B1/en not_active IP Right Cessation
- 1998-08-07 IL IL13443798A patent/IL134437A0/en active IP Right Grant
- 1998-08-07 DE DE69819340T patent/DE69819340T2/en not_active Expired - Lifetime
- 1998-08-07 JP JP2000508685A patent/JP2001514261A/en active Pending
- 1998-08-07 EP EP03077049A patent/EP1378512A1/en not_active Withdrawn
- 1998-08-07 AU AU89896/98A patent/AU760863B2/en not_active Ceased
- 1998-08-18 ZA ZA987445A patent/ZA987445B/en unknown
- 1998-08-19 TW TW087113646A patent/TW419479B/en not_active IP Right Cessation
- 1998-08-21 AR ARP980104157A patent/AR016856A1/en active IP Right Grant
-
2000
- 2000-02-08 IL IL134437A patent/IL134437A/en not_active IP Right Cessation
- 2000-02-28 NO NO20000995A patent/NO324882B1/en not_active IP Right Cessation
- 2000-02-29 HR HR20000110A patent/HRP20000110A2/en not_active Application Discontinuation
-
2001
- 2001-04-03 HK HK01102373A patent/HK1031732A1/en not_active IP Right Cessation
-
2003
- 2003-02-08 CN CN03102165A patent/CN1440972A/en active Pending
-
2004
- 2004-02-25 HK HK04101371A patent/HK1058665A1/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2164515C2 (en) | Campotecin compounds, methods of preparation thereof, intermediates, and therapeutic compositions | |
AU734512B2 (en) | Prodrug forms and new analogues of camptothecin, their use as medicaments | |
RU2194051C2 (en) | Novel analogs of camptothecin, their use as drugs and pharmaceutical compositions comprising thereof | |
US6313135B1 (en) | Analogues of camptothecin, preparation procedures, their application as medicines and the pharmaceutical compositions comprising them | |
AU760863B2 (en) | Optically pure camptothecin analogues, optically pure synthesis intermediate and method for preparing same | |
US6339091B1 (en) | Comptothecin analogues, preparation methods therefor, use thereof as drugs, and pharmaceutical compositions containing said analogues | |
IL144987A (en) | Homocamptothecin derivatives and medicaments containing them | |
US6797715B1 (en) | Analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them | |
RU2190613C2 (en) | Camptothecin analogs, methods of their synthesis and pharmaceutical composition based on thereof | |
US6815546B2 (en) | Analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them | |
MXPA00001944A (en) | Optically pure camptothecin analogues, optically pure synthesis intermediate and method for preparing same | |
MXPA99005768A (en) | Pro-drugs and counterparts of camptothecin, their application as medicines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) |